Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK Alutard SQ Dog is a subcutaneous allergen immunotherapy (SCIT) product containing standardized allergen extracts from dog dander (*Canis familiaris*). Developed by ALK-Abelló, it is indicated for the treatment of moderate-to-severe dog-induced allergic rhinitis and allergic asthma. The extract is adsorbed onto aluminum hydroxide, which acts as an adjuvant and provides a slow-release depot effect at the injection site. The therapy works by modifying the underlying allergic disease through the induction of immune tolerance, characterized by a shift from a Th2-mediated allergic response to a Th1/Treg-mediated response, increased production of IL-10 and TGF-beta, and the generation of allergen-specific IgG4 blocking antibodies that prevent IgE-mediated mast cell degranulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dog dander allergen extract.